Results 131 to 140 of about 1,824,481 (300)

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Public Offering of Securities [PDF]

open access: yes, 2011
Univerzita Karlova v Praze Právnická fakulta Disertační práce Veřejná nabídka cenných papírů Public Offering of Securities Abstrakt v anglickém jazyce Červen 2011 Mgr. Jan Mikuláš Školitel: Prof. JUDr. Stanislava Černá, CSc.
Mikuláš, Jan
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Fort Sheridan CDO Offering Circular [PDF]

open access: yes, 2006
This offering circular serves the interest of Fort Sheridan, Merrill Lynch, and Descap ...
Merrill Lynch International   +1 more
core  

Optimization of seminal extracellular vesicle isolation protocols for cancer biomarker analysis using proteomic profiling

open access: yesMolecular Oncology, EarlyView.
This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan   +8 more
wiley   +1 more source

Monthly Offering

open access: yes
The Monthly Offering...Boston: Anti-Slavery Office, 1841-2 E449 M78 v.
John A. Collins
core  

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

open access: yesMolecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

open access: yesMolecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani   +7 more
wiley   +1 more source

EARNINGS MANAGEMENT AS AN EXPLANATION OF THE EQUITY ISSUE PUZZLE [PDF]

open access: yes
The poor stock price performance of firms that raise capital through seasoned equity offerings is one of the recent puzzles in financial literature. In this study we investigate whether pre-issue earnings management can explain these results for rights ...
María Jesús Pastor, Francisco Poveda
core  

Home - About - Disclaimer - Privacy